Mobile

A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephritis ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-005357-29

A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephritis Due To Systemic Lupus Erythematosus

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To investigate the ability of the ocrelizumab regimen in combination with standard of care treatment (SOC) to induce a complete or partial renal response, as assessed by renal function, urinary sediment and proteinuria in patients with ISN/RPS or WHO class III or IV lupus nephritis.

Critère d'inclusion

  • Lupus Nephritis

Liens